Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sildenafil citrate (Viagra).

G Brock1

  • 1Urology Clinic, St. Joseph's Health Centre, London, Ontario, Canada.

Drugs of Today (Barcelona, Spain : 1998)
|July 25, 2003
PubMed
Summary
This summary is machine-generated.

Sildenafil citrate, a PDE V inhibitor, was initially studied for angina. A surprising side effect of improved erectile function led to its transformation of erectile dysfunction therapy.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An online Sexual Health and Rehabilitation eClinic (TrueNTH SHAReClinic) for prostate cancer patients: a feasibility study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2021
Same author

Screening for cognitive impairment in SLE using the Self-Administered Gerocognitive Exam.

Lupus·2018
Same author

Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open-label studies.

Andrologia·2017
Same author

Ritual and vulnerability.

Journal of religion and health·2013
Same author

Toll-like receptor-associated sequence variants and prostate cancer risk among men of African descent.

Genes and immunity·2013
Same author

Analysis of BK viral infection after alemtuzumab induction for renal transplant.

Transplant infectious disease : an official journal of the Transplantation Society·2011
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Sildenafil citrate, initially developed as an antianginal agent.
  • Investigated in the late 1980s by Pfizer under the designation 92-480-10.

Purpose of the Study:

  • To explore the therapeutic potential of sildenafil citrate.
  • To investigate the unexpected side effects observed during clinical trials.

Main Methods:

  • Clinical investigations of sildenafil citrate.
  • Observation of patient-reported side effects.

Main Results:

  • Sildenafil citrate demonstrated an unexpected improvement in erectile function.
  • This serendipitous finding revolutionized erectile dysfunction treatment.

Conclusions:

  • Sildenafil citrate's oral route and broad efficacy transformed erectile dysfunction therapy.
  • The drug's efficacy across various etiologies underscores its significance.